[1]谈春晓.胃泌素17和胃蛋白酶原血清学联合检测对胃癌高危人群筛查的临床价值[J].医学信息,2020,33(24):71-73.[doi:10.3969/j.issn.1006-1959.2020.24.020]
　TAN Chun-xiao.The Clinical Value of the Combined Detection of Gastrin 17 and Pepsinogen Serology in Screening High-risk Groups of Gastric Cancer[J].Medical Information,2020,33(24):71-73.[doi:10.3969/j.issn.1006-1959.2020.24.020]
点击复制

胃泌素17和胃蛋白酶原血清学联合检测对胃癌高危人群筛查的临床价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年24期
页码:
71-73
栏目:
论著
出版日期:
2020-12-15

文章信息/Info

Title:
The Clinical Value of the Combined Detection of Gastrin 17 and Pepsinogen Serology in Screening High-risk Groups of Gastric Cancer
文章编号:
1006-1959（2020）24-0071-03
作者:
谈春晓
无锡市第二人民医院消化内科消化内镜室，江苏 无锡 214002
Author(s):
TAN Chun-xiao
Digestive Endoscopy Room,Department of Gastroenterology,Wuxi Second People’s Hospital,Wuxi 214002,Jiangsu,China
关键词:
胃泌素17; 胃蛋白酶原; 胃癌
Keywords:
Gastrin 17; Pepsinogen; Gastric cancer
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2020.24.020
文献标志码:
A
摘要:
目的 探讨应用胃泌素17和胃蛋白酶原血清学联合检测对于胃癌高危人群进行胃癌筛查的临床价值。方法 选取2017年9月~2019年1月我院接受胃癌筛查的457例胃癌高危人群病例作为研究对象，采用ELISA检测血清胃泌素17（G-17）、胃蛋白酶原PGⅠ、PGⅡ水平，根据其结果将G-17（-）PG（-）设为A组，G-17（+）PG（-）设为B组、G-17（-）PG（+）设为C组、G-17（+）PG（+）设为D组，以胃镜及病理活检结果作为金标准，比较各组胃癌检出率，分析G-17和PG诊断胃癌的临床价值。结果 457例患者共检出胃癌12例，其中早期胃癌8例，进展期胃癌4例，胃癌检出率2.63%。A、B、C、D组胃癌检出率分别为0.42%（1/236）、4.63%（5/108）、2.41%（2/83）、13.33%（4/30），A组胃癌检出率低于其他三组，差异有统计学意义（P＜0.05）。血清学联合检测结果中与胃镜检查一致率为92.56%，阳性预测值为13.33%，阴性预测值为98.13%。ROC曲线分析显示，G-17、PGR、PGⅠ的ROC曲线下面积分别为0．769、0.742、0.708，最佳诊断临界值分别为14.63 pmol/L、7.08、56.69 μg/ml。结论 胃泌素17和胃蛋白酶原血清学联合检测方法具有无创有效且简单易行的特点，能为胃癌诊断提供良好的依据，适宜作为胃癌初筛的检查手段。
Abstract:
Objective To investigate the clinical value of combined detection of gastrin 17 and pepsinogen serology for gastric cancer screening in high risk population of gastric cancer.Methods Selected 457 cases of high-risk gastric cancer patients who were screened for gastric cancer in our hospital from September 2017 to January 2019 as the research objects. ELISA was used to detect the levels of serum gastrin 17 (G-17), pepsinogen PGⅠ, and PGⅡ. As a result, G-17(-)PG(-) was set to group A, G-17(+)PG(-) was set to group B, G-17(-)PG(+) was set to group C, G- 17(+)PG(+) was set as group D, and gastroscopy and pathological biopsy results were used as the gold standard to compare the detection rates of gastric cancer in each group, and analyzed the clinical value of G-17 and PG in the diagnosis of gastric cancer.Results A total of 12 cases of gastric cancer were detected in 457 patients, including 8 cases of early gastric cancer and 4 cases of advanced gastric cancer. The detection rate of gastric cancer was 2.63%. The detection rates of gastric cancer in groups A, B, C, and D were 0.42% (1/236), 4.63% (5/108), 2.41% (2/83), 13.33% (4/30), respectively.The detection rate of gastric cancer in group A was lower than the other three groups, the difference was statistically significant (P<0.05). The concordance rate of the combined serological test with gastroscopy was 92.56%, the positive predictive value was 13.33%, and the negative predictive value was 98.13%. ROC curve analysis showed that the area under the ROC curve of G-17, PGR, and PGI were 0.769, 0.742, and 0.708, respectively, and the best diagnostic cutoff values were 14.63 pmol/L, 7.08, and 56.69 μg/ml, respectively.Conclusion The combined detection of gastrin 17 and pepsinogen serology is noninvasive,effective and simple. It can provide a good basis for the diagnosis of gastric cancer. It is suitable for gastric cancer screening.

参考文献/References:

[1]陈万青,郑荣寿,张思维,等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2016,25(1):l-8. [2]徐娟,张承顺.血清胃蛋白酶原和胃泌素17水平对老年胃癌患者的临床意义[J].肿瘤研究与临床,2018,30(11):771-773. [3]李晓琴,单文杰,董文福,等.胃蛋白酶原和胃泌素对萎缩性胃炎、胃癌的筛查价值及与幽门螺旋杆菌感染的关系[J].宁夏医科大学学报,2017,39(9):1062-1065. [4]孟丽英.萎缩性胃炎患者血清胃泌素-17及胃蛋白酶原水平检测及临床意义[J].山西医药杂志,2018,47(22):60-62. [5]苏惠玲.慢性萎缩性胃炎患者血清胃蛋白酶原、胃泌素17水平及其临床意义[J].中国实用医刊,2020,47(5):33-36. [6]吴永伟,赵刚.CEA、CA724、CA199与PGI、PGII、PGR联合检测在胃癌早期诊断中的价值分析[J].川北医学院学报,2018,33(6):38-41. [7]盛一洁.血清胃蛋白酶原和胃泌素水平检测评估早期胃癌风险的应用研究[J].中国实用乡村医生杂志,2019,26(12):39-41. [8]江唯波.血清胃蛋白酶原、CEA、CA199、CA724与胃泌素17联合检测在胃癌早期诊断中的应用价值分析[J].中国中西医结合消化杂志,2017,25(11):833-836. [9]Zhou XF,Zhang W.Application of serum pepsinogen,gastrin 17,CA72-4,CA199,and CA125 in gastric cancer screening[J].World Chinese Journal of Digestology,2018,26(15):939-944. [10]郝思香.血清胃蛋白酶原及CA199、CA242、CEA联合检测在胃癌早期诊断中的价值[J].临床检验杂志(电子版),2019,8(3):170-171. [11]韩梅,连俊,马明杰,等.血清胃蛋白酶原与肿瘤标志物CEA,CA199,CA242,CA724联合检测对胃癌诊断的价值分析[J].河北医药,2019,41(23):3574-3577. [12]张小丽,张翠,邹德勇,等.血清胃蛋白酶原检测518例胃癌的临床应用[J].武警后勤学院学报,2016(10):825-827. [13]方军,严林虎,王毅方,等.血清胃蛋白酶原联合胃泌素-17对胃癌普查的临床意义[J].岭南急诊医学杂志,2017,22(4):341-343. [14]闫真,邵淑琳,张杰,等.血清胃蛋白酶原联合胃泌素17检测在胃癌筛查中的价值[J].中国医药,2016,11(12):1795-1799.

相似文献/References:

[1]潮子健,汪文生,谢宏伟.年龄对胃部常见良性疾病患者的胃蛋白酶原及胃泌素-17水平的影响[J].医学信息,2018,31(23):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
　CHAO Zi-jian,WANG Wen-sheng,XIE Hong-wei.Effect of Age on Pepsinogen and Gastrin-17 Levels in Patients with Common Benign Diseases of the Stomach[J].Medical Information,2018,31(24):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
[2]方年富,何庆霞,杨卫生,等.胃蛋白酶原与胃泌素-17在胃癌前病变筛查中的价值[J].医学信息,2019,32(22):170.[doi:10.3969/j.issn.1006-1959.2019.22.060]
　FANG Nian-fu,HE Qing-xia,YANG Wei-sheng,et al.The Value of Pepsinogen and Gastrin-17 in the Screening of Gastric Precancerous Lesions[J].Medical Information,2019,32(24):170.[doi:10.3969/j.issn.1006-1959.2019.22.060]
[3]李 杰.奥美拉唑联合铝碳酸镁对反流性食管炎患者临床症状及血清胃泌素水平的影响[J].医学信息,2022,35(06):153.[doi:10.3969/j.issn.1006-1959.2022.06.039]
　LI Jie.Effect of Omeprazole Combined with Aluminum Magnesium Carbonate on Clinical Symptoms and Serum Gastrin Level in Patients with Reflux Esophagitis[J].Medical Information,2022,35(24):153.[doi:10.3969/j.issn.1006-1959.2022.06.039]
[4]敖先伟,陈小银,孔繁静,等.荆州地区回族与汉族胃癌及胃溃疡患者血液胃蛋白酶原水平比较[J].医学信息,2024,37(03):57.[doi:10.3969/j.issn.1006-1959.2024.03.010]
　AO Xian-wei,CHEN Xiao-yin,KONG Fan-jing,et al.Comparative of Serum Pepsinogen in Hui and Han Nationalities Patients with Gastric Cancer and Gastric Ulcer in Jingzhou Area[J].Medical Information,2024,37(24):57.[doi:10.3969/j.issn.1006-1959.2024.03.010]
[5]茅溢恒.幽门螺杆菌抗体、胃泌素17、胃蛋白酶原等联合检测 在体检人群胃疾病筛查中的意义[J].医学信息,2018,31(11):22.[doi:10.3969/j.issn.1006-1959.2018.11.007]
　MAO Yi-heng.The Significance of Combined Detection of Helicobacter Pylori Antibody,Gastrin 17, Pepsinogen,etc.in Gastric Disease Screening in Physical Examination Population[J].Medical Information,2018,31(24):22.[doi:10.3969/j.issn.1006-1959.2018.11.007]
[6]王 贝,刘凯歌.血清胃蛋白酶Ⅰ、Ⅱ和胃泌素17在腹泻患者中的表达及其意义[J].医学信息,2020,33(22):92.[doi:10.3969/j.issn.1006-1959.2020.22.026]
　WANG Bei,LIU Kai-ge.Expression and Significance of Serum Pepsin Ⅰ,Ⅱ and Gastrin 17 in Patients with Diarrhea[J].Medical Information,2020,33(24):92.[doi:10.3969/j.issn.1006-1959.2020.22.026]
[7]姚 肖,刘凯歌.胃泌素17、胃蛋白酶原检测对早期胃癌筛查的意义[J].医学信息,2021,34(02):98.[doi:10.3969/j.issn.1006-1959.2021.02.026]
　YAO Xiao,LIU Kai-ge.Significance of Gastrin 17,Pepsinogen Detection for Early Gastric Cancer Screening[J].Medical Information,2021,34(24):98.[doi:10.3969/j.issn.1006-1959.2021.02.026]

更新日期/Last Update: 1900-01-01